Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate UpdatePoxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress
PXL770, a novel direct AMP kinase activator, observed to reduce liver inflammatory cells, which may contribute to an improvement of fibrogenesis, in a preclinical NASH model Clinical results from the PXL770 PK/PD…
Read this Press Release: Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH CongressPoxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
